Drug Trial Radar · NCT05669014
A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)
Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Dec 4, 2023
Primary completion
Jul 2, 2025
Study completion Jul 2, 2025
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Dec 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary efficacy objective: To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24. The secondary efficacy objectives include: 1. To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24. 2. To evaluate the effect of daxdilimab compared with placebo on skin symptoms at Week 24. 3. To evaluate the effect of daxdilimab on decreasing the use of corticosteroid at Week 24. Other secondary objectives include: 1. To characterize the pharmacokinetics (PK) and immunogenicity of daxdilimab in participants. 2. To evaluate the safety and tolerability of daxdilimab in participants.
Conditions
- Idiopathic Inflammatory Myositis
Interventions
DaxdilimabDrug
Participants will be administered daxdilimab by subcutaneous (SC) injection.
PlaceboDrug
Participants will be administered identically matching placebo by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Total Improvement Score (TIS) at Week 24Time frame: At Week 24
Locations
9 sites in 6 countries. Site status is shown where the registry gives one.
Advanced Research Center, Inc.
Anaheim, California
Centro Mineiro de Pesquisa - CMiP
Juiz de Fora, Minas Gerais, Brazil
LMK Servicos Medicos SS
Porto Alegre, Rio Grande do Sul, Brazil
Revmatologicky ustav
Prague, Praha, Hlavní Mesto, Czechia
Unidad de Investigacion de las Enfermedades Reumaticas S.A. De C.V.
Mexico City, Mexico
Accelerium, S. de R.L. de C.V. - PPDS
Monterrey, Mexico
Hospital Quironsalud Infanta Luisa
Seville, Spain
Aintree University Hospital - NWCRN - PPDS
Liverpool, Merseyside, United Kingdom
Western General Hospital Edinburgh - PPDS
Edinburgh, Midlothian, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.